Actively Recruiting
Comparing Melatonin and Placebo for Mood Stabilization in Adults with Bipolar Disorder in a 6-Month Randomized Trial
Led by Lars Vedel Kessing · Updated on 2026-05-12
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying bipolar disorder, focusing on how adding melatonin compares to a placebo in helping stabilize mood and improve important patient outcomes. This randomized controlled trial aims to evaluate whether melatonin has antimanic, antidepressant, or relapse-preventing effects over six months. Sleep problems are common in bipolar disorder and affect mood phases, so this study explores melatonins potential role as a key hormone regulating sleep and circadian rhythms. The study involves two groups of patients with bipolar disorder. One group will receive 6 mg of melatonin each evening, while the other group will receive a placebo capsule. Both patients and researchers will be unaware of which treatment each participant receives, ensuring a double-blind setup. The trial will last for six months, during which the effects on mood stabilization and other outcomes will be examined. Participants will undergo assessments throughout the six months to track mood stabilization, sleep quality, and changes in depression symptoms. Researchers will use interviews and clinical evaluations to measure these outcomes at baseline, three months, and six months. The study includes safety monitoring and informed consent, with all care and medication provided as part of the trial process.
CONDITIONS
Brief Title
Melatonin Versus Placebo for Bipolar Disorder
Research Team
L
Lars Kessing
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here